Table 1.
Patient characteristics
| Analysis 1 | Analysis 2 | Analysis 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Pre-treatment, n = 103 | Control, n = 39 | p value | Pre-treatment, n = 103 | Post-treatment, n = 103 | p value | Post-treatment, n = 103 | Control, n = 39 | p value | |
| Age, years | 0.0573 | 0.4131 | 0.0130 | ||||||
| Mean (SD, range) | 31.9 (5.2, 25–45) | 30.1 (4.4, 20–43) | 31.9 (5.2, 25–45) | 32.5 (5.3, 25–46) | 32.5 (5.3, 25–46) | 30.1 (4.4, 20–43) | |||
| Ethnicity, n/N (%) | 0.0659 | > 0.9999 | 0.0659 | ||||||
| Caucasian | 87/103 (85) | 30/39 (77) | 87/103 (85) | 87/103 (85) | 87/103 (85) | 30/39 (77) | |||
| Asian | 10/103 (10) | 2/39 (5) | 10/103 (10) | 10/103 (10) | 10/103 (10) | 2/39 (5) | |||
| Black | 6/103 (5) | 7/39 (18) | 6/103 (5) | 6/103 (5) | 6/103 (5) | 7/39 (18) | |||
| Parity, n/N (%) | 0.5329 | > 0.9999 | 0.5329 | ||||||
| Nulliparous | 73/103 (71) | 30/39 (76) | 73/103 (71) | 73/103 (71) | 73/103 (71) | 30/39 (76) | |||
| Parous | 30/103 (29) | 9/39 (24) | 30/103 (29) | 30/103 (29) | 30/103 (29) | 9/39 (24) | |||
| Smoking status, n/N (%) | 0.1909 | > 0.9999 | 0.2647 | ||||||
| Current smoker | 27/103 (26) | 6/39 (15) | 27/103 (26) | 26/103 (25) | 26/103 (25) | 6/39 (15) | |||
| Non-smoker | 76/103 (74) | 33/39 (85) | 76/103 (74) | 77/103 (75) | 77/103 (75) | 33/39 (85) | |||
| Phase of menstrual cycle, n/N (%) | 0.6472 | 0.4655 | 0.5388 | ||||||
| Luteal | 55/103 (53) | 23/39 (58) | 55/103 (53) | 50/103 (48) | 50/103 (48) | 23/39 (58) | |||
| Follicular | 38/103 (37) | 14/39 (36) | 38/103 (37) | 46/103 (46) | 46/103 (46) | 14/39 (36) | |||
| Unknown | 10/103 (10) | 2/39 (5) | 10/103 (10) | 7/103 (7) | 7/103 (7) | 2/39 (5) | |||
| Contraception, n/N (%) | 0.7316 | 0.9982 | 0.6958 | ||||||
| Nil | 35/103 (34) | 19/39 (49) | 35/103 (34) | 34/103 (33) | 34/103 (33) | 19/39 (49) | |||
| Condoms | 17/103 (16) | 5/39 (13) | 17/103 (16) | 18/103 (17) | 18/103 (17) | 5/39 (13) | |||
| COCP | 37/103 (36) | 12/39 (31) | 37/103 (36) | 37/103 (36) | 37/103 (36) | 12/39 (31) | |||
| POP | 5/103 (5) | 1/39 (2) | 5/103 (5) | 5/103 (5) | 5/103 (5) | 1/39 (2) | |||
| Copper IUD | 2/103 (2) | 0/39 (0) | 2/103 (2) | 1/103 (1) | 1/103 (1) | 0/39 (0) | |||
| Mirena IUS | 5/103 (5) | 1/39 (2) | 5/103 (5) | 6/103 (6) | 6/103 (6) | 1/39 (2) | |||
| Contraceptive implant | 2/103 (2) | 1/39 (2) | 2/103 (2) | 2/103 (2) | 2/103 (2) | 1/39 (2) | |||
| Time since last intercourse, n/N (%) | 0.7684 | > 0.9999 | 0.7684 | ||||||
| > 48 h | 92/103 (89) | 34/39 (87) | 92/103 (89) | 92/103 (89) | 92/103 (89) | 34/39 (87) | |||
| < 48 h | 11/103 (11) | 5/39 (13) | 11/103 (11) | 11/103 (11) | 11/103 (11) | 5/39 (13) | |||
| HPV status | – | – | – | – | – | ||||
| Negative | – | – | – | – | 82/103 (80) | 23/39 (59) | |||
| Positive | – | – | – | – | 21/103 (20) | 12/39 (31) | |||
| Unknown | – | – | – | – | 0/103 (0) | 4/39 (10) | |||
| Cytology | |||||||||
| Negative | – | – | – | – | 81/103 (79) | 39/39 (100) | |||
| Borderline nuclear changes | – | – | – | – | 17/103 (16) | 0/39 (0) | |||
| LSIL | – | – | – | – | 3/103 (3) | 0/39 (0) | |||
| HSIL | – | – | – | – | 2/103 (2) | 0/39 (0) | |||
| Cytology and HPV status | – | – | – | – | – | ||||
| Normal, HPV-ve | – | – | – | – | 70/103 (69) | 23/39 (59) | |||
| Normal, HPV+ve | – | – | – | – | 11/103 (10) | 12/39 (31) | |||
| Normal, HPV status unknown | – | – | – | – | 0/103 (0) | 4/39 (10) | |||
| BNC, HPV-ve | – | – | – | 12/103 (11) | 12/103 (11) | 0/39 (0) | |||
| BNC, HPV+ve | – | – | – | 5/103 (5) | 5/103 (5) | 0/39 (0) | |||
| LSIL, HPV-ve | – | – | – | 0/103 (0) | 0/103 (0) | 0/39 (0) | |||
| LSIL, HPV+ve | – | – | – | 3/103 (3) | 3/103 (3) | 0/39 (0) | |||
| HSIL | – | – | – | 2/103 (2) | 2/103 (2) | 0/39 (0) | |||
BNC borderline nuclear changes, CIN cervical intraepithelial neoplasia, COCP combined oral contraceptive pill, HSIL high-grade squamous intraepithelial neoplasia, HPV human papillomavirus, IUD intrauterine device, IUS intrauterine system, LSIL low-grade squamous intraepithelial neoplasia, POP progesterone-only pill, SD standard deviation